# US 2025/0082633 A1 · Compounds and methods for modulating splicing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082633 A1
- Document ID: US20250082633A1
- Status: Published application
- Kind: A1
- Application number: 18/713,561
- Filed: 2022-11-23
- Published: 2025-03-13
- Earliest claimed: 2021-11-24
- Assignees: Remix Therapeutics Inc.
- Applicants: Remix Therapeutics Inc.
- Inventors: Dominic Reynolds; Michael W. Seiler; Anant A. Agrawal; Frederic Vaillancourt; Peter Smith; Sudeep Prajapati; Allen t. Hopper; Stepan Vyskocil; Benoit Moreau
- Web page: https://patentgrep.com/patent/US20250082633A1

## CPC

- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:
A and B are each independently cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R1;
L is absent, C1-C6-alkylene, C1-C6-heteroalkylene, C(O), or —C(O)N(RB)—, wherein each alkylene and heteroalkylene is optionally substituted with one or more R8;
W, X, Z1, and Z2 are each independently C(R3) or N, wherein at least one of W and X is N;
each R1 is independently hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, C1-C6 alkylene-aryl, C2-C6 alkenylene-aryl, C1-C6 heteroalkylene-aryl, heteroaryl, C1-C6 alkylene-heteroaryl, C1-C6 heteroalkylene-heteroaryl, halo, cyano, oxo, —ORA, —NRBRC, —NRBC(O)RD, —NO2, —C(O)NRBRC, —C(O)RD, —C(O)ORD, or —S(O)xRD, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R4; or
two R1 groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R4;
R2 is hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, —C(O)RD, or —ORA; wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5;
R3 is hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, —C(O)RD, or —ORA; wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5;
each R4 is independently C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, —ORA, —NRBRC, —NRBC(O)RD, —NO2, —C(O)NRBRC, —C(O)RD, —C(O)ORD, or —S(O)xRD, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6;
each R5 is C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, —ORA, —NRBRC, —NRBC(O)RD, —NO2, —C(O)NRBRC, —C(O)RD, —C(O)ORD, or —S(O)xRD;
each R6 is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or —ORA;
each RA is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6 alkylene-aryl, C1-C6 alkylene-heteroaryl, —C(O)RD, or —S(O)xRD;
each of RB and RC is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)RD, or —S(O)xRD; or
RB and RC together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more R7;
each RD is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C1-C6 alkylene-aryl, or C1-C6 alkylene-heteroaryl;
each R7 and R8 is independently C1-C6-alkyl, halo, cyano, oxo, or —ORA1;
each RA1 is hydrogen or C1-C6-alkyl; and
x is 0, 1, or 2.

### Claim 2 (depends on 1)

The compound of claim 1, wherein each of A and B is independently heteroaryl or heterocyclyl, each of which is optionally substituted with one or more R1.

### Claim 3

The compound of any one of the preceding claims, wherein one of A and B is independently a monocyclic heteroaryl or bicyclic heteroaryl, each of which is optionally substituted with one or more R1.

### Claim 4

The compound of any one of the preceding claims, wherein one of A and B is independently a bicyclic heteroaryl optionally substituted with one or more R1.

### Claim 5

The compound of any one of the preceding claims, wherein one of A and B is independently a nitrogen-containing heteroaryl optionally substituted with one or more R1.

### Claim 6

The compound of any one of the preceding claims, wherein one of A and B is a 5-10 membered heteroaryl optionally substituted with one or more R1.

### Claim 7 (depends on 1)

The compound of any one of the preceding claims, wherein one of A and B is independently selected from
wherein R1 is as described in claim 1.

### Claim 8 (depends on 1)

The compound of any one of the preceding claims, wherein one of A and B is independently selected from
wherein R1 is as described in claim 1.

### Claim 9

The compound of any one of the preceding claims, wherein one of A and B is independently selected from
wherein each R1 is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or —ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R4.

### Claim 10

The compound of any one of the preceding claims, wherein one of A and B is independently
wherein each R1 is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or —ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R4.

### Claim 11 (depends on 1)

The compound of any one of the preceding claims, wherein A is selected from
wherein R1 is as described in claim 1.

### Claim 12 (depends on 1)

The compound of any one of the preceding claims, wherein B is selected from
wherein R1 is as described in claim 1.

### Claim 13

The compound of any one of the preceding claims, wherein A is selected from
wherein each R1a is independently C1-C6-alkyl, C1-C6-heteroalkyl, C1-C6-haloalkyl, halo, cyano, or —ORA, and each alkyl, heteroalkyl, and haloalkyl is optionally substituted with one or more R4.

### Claim 14 (depends on 1)

The compound of any one of the preceding claims, wherein A is
wherein R1 is as described in claim 1.

### Claim 15 (depends on 1)

The compound of any one of the preceding claims, wherein B is
wherein R1 is as described in claim 1.

### Claim 16

The compound of any one of the preceding claims, wherein one of A and B is independently selected from

### Claim 17

The compound of any one of the preceding claims, wherein one of A and B is independently selected from

### Claim 18

The compound of any one of the preceding claims, wherein one of A and B is independently selected from

### Claim 19

The compound of any one of the preceding claims, wherein A is selected from

### Claim 20

The compound of any one of the preceding claims, wherein B is selected from

### Claim 21

The compound of any one of the preceding claims, wherein A selected from

### Claim 22

The compound of any one of the preceding claims, wherein B selected from

### Claim 23

The compound of any one of the preceding claims, wherein one of A and B is independently a monocyclic heterocyclyl or bicyclic heterocyclyl, each of which is optionally substituted with one or more R1.

### Claim 24

The compound of any one of the preceding claims, wherein one of A and B is independently a nitrogen-containing heterocyclyl optionally substituted with one or more R1.

### Claim 25

The compound of any one of the preceding claims, wherein one of A and B is independently a 4-8 membered heterocyclyl optionally substituted with one or more R1.

### Claim 26 (depends on 1)

The compound of any one of the preceding claims, wherein one of A and B is independently selected from
wherein R1 is as described in claim 1.

### Claim 27 (depends on 1)

The compound of any one of the preceding claims, wherein one of A and B is independently selected from
wherein R1 is as described in claim 1.

### Claim 28 (depends on 1)

The compound of any one of the preceding claims, wherein one of A and B is
wherein R1 is as described in claim 1.

### Claim 29 (depends on 1)

The compound of any one of the preceding claims, wherein A is
and R1 is as described in claim 1.

### Claim 30 (depends on 1)

The compound of any one of the preceding claims, wherein B is selected from
wherein R1 is as described in claim 1.

### Claim 31 (depends on 1)

The compound of any one of the preceding claims, wherein B is
wherein R1 is as described in claim 1.

### Claim 32

The compound of any one of the preceding claims, wherein one of A and B is independently selected from

### Claim 33

The compound of any one of the preceding claims, wherein one of A and B is independently selected from

### Claim 34

The compound of any one of the preceding claims, wherein one of A and B is

### Claim 35

The compound of any one of the preceding claims, wherein A is selected from

### Claim 36

The compound of any one of the preceding claims, wherein B is selected from

### Claim 37

The compound of any one of the preceding claims, wherein A is selected from

### Claim 38

The compound of any one of the preceding claims, wherein B is selected from

### Claim 39

The compound of any one of the preceding claims, wherein X is N.

### Claim 40

The compound of any one of the preceding claims, wherein W is N.

### Claim 41

The compound of any one of the preceding claims, wherein both of W and X is independently N.

### Claim 42

The compound of any one of the preceding claims, wherein Z1 is C(R3) (e.g., CH).

### Claim 43

The compound of any one of the preceding claims, wherein Z1 is N.

### Claim 44

The compound of any one of the preceding claims, wherein X is N and W, Z1, and Z2 are each independently C(R3).

### Claim 45

The compound of any one of the preceding claims, wherein X and Z1 are each independently N, and W and Z2 are each independently C(R3).

### Claim 46

The compound of any one of the preceding claims, wherein X and W are each independently N and Z1 is C(R3).

### Claim 47

The compound of any one of the preceding claims, wherein each of W, X, and Z1 are each independently N, and Z1 is C(R3).

### Claim 48

The compound of any one of the preceding claims, wherein R2 is hydrogen.

### Claim 49

The compound of any one of the preceding claims, wherein R2 is C1-C6-alkyl, halo, or —ORA.

### Claim 50

The compound of any one of the preceding claims, wherein R2 is —CH3, —Cl, —F, —OCH3, or

### Claim 51

The compound of any one of the preceding claims, wherein L is absent or C1-C6-alkylene optionally substituted with one or more R8.

### Claim 52

The compound of any one of the preceding claims, wherein L is absent.

### Claim 53 (depends on 1)

The compound of any one of the preceding claims, wherein the compound of Formula (I) is Formula (I-a):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, W, X, Z1, Z2, R2 and subvariables thereof are as defined in claim 1.

### Claim 54 (depends on 1)

The compound of any one of the preceding claims, wherein the compound of Formula (I) is Formula (I-b):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of A, B, W, X, Z1, R2, R3, and subvariables thereof is as defined in claim 1.

### Claim 55 (depends on 1)

The compound of any one of the preceding claims, wherein the compound of Formula (I) is Formula (I-c):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of A, B, W, Z1, R2, R3 and subvariables thereof is as defined in claim 1.

### Claim 56 (depends on 1)

The compound of any one of the preceding claims, wherein the compound of Formula (I) is Formula (I-d):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, W, Z1, R2, R3 and subvariables thereof are as defined in claim 1.

### Claim 57 (depends on 1)

The compound of any one of the preceding claims, wherein the compound of Formula (I) is a compound of Formula (I-e):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of A, B, W, R2, R3 and subvariables thereof are defined as in claim 1.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The compound of any one of claims 1-53, wherein the compound of Formula (I) is a compound of Formula (I-f):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of A, B, W, R2, m, and subvariables thereof are defined as in claim 1.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The compound of any one of claims 1-54, wherein the compound of Formula (I) is a compound of Formula (I-g):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of A, B, W, R2, and subvariables thereof are defined as in claim 1.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-h):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of A, B, W, R2, and subvariables thereof are defined as in claim 1.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The compound of any one of claims 1-50, wherein the compound of Formula (I) is a compound of Formula (I-i):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein A, B, W, X, Z1, Z2, and R2 are as defined in claim 1; each R8a and R8b is independently C1-C6-alkyl, halo, cyano, oxo, or —ORA1; and y is 0, 1, 2, 3, or 4.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The compound of any one of claims 1-50, wherein the compound of Formula (I) is a compound of Formula (I-j):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each R1a, R1b, R1c, R8a and R8b is independently C1-C6-alkyl, halo, cyano, oxo, or —ORA1; X1 is C(R1) or N; X2 is C(R1)2 or N(R1); y is 0, 1, 2, 3, or 4; and W, X, Z1, Z2, R1 and R2 are as defined in claim 1.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-k):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of X1 and X3 is independently C(R3) or N; X2 is C or N; and wherein A, Z1, R1, R2, and R3 are as defined in claim 1.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-l):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of R1a, R1b, and R1c is independently hydrogen, C1-C6-alkyl, halo, or —ORA; and wherein A, RA, Z1, R1, R2, and R3 are as defined in claim 1.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-m):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of X1 and X3 is independently C(R1) or N; X2 is C or N; and wherein A, Z1, R1 and R2 are as defined in claim 1.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-n):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of R1a and R1b is independently hydrogen, C1-C6-alkyl, halo, or —ORA; and wherein A, RA, Z1, R1, R2, and R3 are as defined in claim 1.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-0):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of X1 and X2 is independently C(R1) or N; and wherein A, Z1, R1 and R2 are as defined in claim 1.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-p):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of R1a, R1b, and R1c is independently hydrogen, C1-C6-alkyl, halo, or —ORA; and
wherein A, RA, Z1, R1 and R2 are as defined in claim 1.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-q):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein X1 is C(R1); X2 is C(R1)2 or N(R1); and wherein B, Z1, R1, R2 and R3 are as defined in claim 1.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-r):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of R1c, R1d and R1e is independently hydrogen, alkyl, halo, or heteroalkyl; or R1d and R1c together with the atoms to which they are attached, form a three or four membered cycloalkyl group; and wherein each of B, Z1, Z2, R2, and R3 are as defined as in claim 1.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-s):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein X1 is C(R1); X2 is C(R1)2 or N(R1); each of R1a, R1b, and R1c is independently hydrogen, C1-C6-alkyl, halo, or —ORA and wherein RA, Z1, R1, R2, and R3 are as defined in claim 1.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-t):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein X1 is C(R1); X2 is C(R1)2 or N(R1); each of R1a, R1b, and R1c is independently hydrogen, C1-C6-alkyl, halo, or —ORA and wherein RA, Z1, R1, and R2 are as defined in claim 1.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-u):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein X1 is C(R1); X2 is C(R1)2 or N(R1); each of R1a and R1b is independently hydrogen, C1-C6-alkyl, halo, or —ORA and wherein RA, Z1, R1, and R2 are as defined in claim 1.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, wherein the compound of Formula (I) is a compound of Formula (I-v):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein each of R1a, R1b, R1c, R1d, R1e, and R1f is independently hydrogen, C1-C6-alkyl, halo, or RA; and wherein RA, Z1, R1, and R2 are as defined in claim 1.

### Claim 75

The compound of the preceding claims, wherein:
A and B are each independently selected from heteroaryl (e.g., bicyclic heteroaryl) optionally substituted with R1 and heterocyclyl (e.g., monocyclic heterocyclyl) optionally substituted with one or more R1; and
m is 0 or 1; and
R2 is C1-C6-alkyl, halo, or —ORA.

### Claim 76

The compound of any one of the preceding claims, wherein when Z1 is N, B is bicyclic heteroaryl optionally substituted with one or more R1, wherein at least one R1 comprises an oxygen atom.

### Claim 77

The compound of any one of the preceding claims, wherein the compound is selected from a compound listed in Table 1, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

### Claim 78

A pharmaceutical composition comprising a compound of any one of the preceding claims and a pharmaceutically acceptable excipient.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The compound of any one of claims 1-77, or the pharmaceutical composition of claim 78, wherein the compound alters a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The compound of any one of claims 1-77, or the pharmaceutical composition of claim 78, wherein the compound binds to a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The compound of any one of claims 1-77, or the pharmaceutical composition of claim 78, wherein the compound stabilizes a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA).

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The compound of any one of claims 1-77, or the pharmaceutical composition of claim 78, wherein the compound increases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The compound of any one of claims 1-77, or the pharmaceutical composition of claim 78, wherein the compound decreases splicing at splice site on a target nucleic acid (e.g., an RNA, e.g., a pre-mRNA), by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, e.g., as determined by qPCR %.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

A method of forming a complex comprising a component of a spliceosome (e.g., a major spliceosome component or a minor spliceosome component), a nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA), and a compound of Formula (I) or a composition thereof according to any one of claims 1-77 and the pharmaceutical composition of claim 78:
comprising contacting the nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA) with a compound of Formula (I).

### Claim 85 (depends on 84)

The method of claim 84, wherein the component of a spliceosome is recruited to the nucleic acid in the presence of the compound of Formula (I).

### Claim 86 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

A method of altering the conformation of a nucleic acid (e.g., a DNA, RNA, e.g., a pre-mRNA) comprising contacting the nucleic acid with a compound of Formula (I) according to any one of claims 1-77, or the pharmaceutical composition of claim 78.

### Claim 87 (depends on 86)

The method of claim 86, wherein the altering comprises forming a bulge in the nucleic acid.

### Claim 88 (depends on 86)

The method of claim 86, wherein the altering comprises stabilizing a bulge in the nucleic acid.

### Claim 89 (depends on 86)

The method of claim 86, wherein the altering comprises reducing a bulge in the nucleic acid.

### Claim 90 (depends on 86, 87, 88, 89)

The method of any one of any one of claims 86-89, wherein the nucleic acid comprises a splice site.

### Claim 91 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

A method for treating a disease or disorder in a subject comprising administering to the subject a compound of Formula (I) according to any one of claims 1-77 or the pharmaceutical composition of claim 78.

### Claim 92 (depends on 91)

The method of claim 91, wherein the disease or disorder comprises a proliferative disease (e.g., cancer, a benign neoplasm, or angiogenesis).

### Claim 93 (depends on 91, 92)

The method of any one of claims 91-92, wherein the proliferative disease is cancer.

### Claim 94 (depends on 91)

The method of claim 91, wherein the disease or disorder comprises a neurological disease or disorder, autoimmune disease or disorder, immunodeficiency disease or disorder, lysosomal storage disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, respiratory disease or disorder, renal disease or disorder, or infectious disease.

### Claim 95 (depends on 94)

The method of claim 94, wherein the disease or disorder comprises neurological disease or disorder.

### Claim 96 (depends on 95)

The method of claim 95, wherein the disease or disorder comprises Huntington's disease.
